Abstract
The authors have carried out the laboratory and clinical studies of PC-904. The results were as follows;
The sensitivity was measured by plate dilution method on 32 strains of Staph. aureus, 32 strains of P.aeruginosa, 12 strains of E. coli, and 15 strains of Kl.pneumoniae. The sensitivity distribution of P.aeruginosa was 0.78-6.25μg/ml and the peak was 1.56μg/ml. PC-904 inhibited the growth of all of P.aeruzinosa at less than 6.25μg/ml. The peak of sensitivity distribution of Staph.aureus was 0.78-1.56μg/ml and 50μg/ml. PC-904 inhibited the growth of 47% of E.coli at less than 50μg/ml but Kl.pneumoniae was not sensitive to this agent.
PC-904 was given by intravenous in or by drip infusion (for 1 hour) at dose of 25mg/kg body weight to 2 children. The serum levels of PC-904 were 204, 62 and 34 μg/ml at 0.5, 1 and 2 hours after intravenous administration, respectively, and. level at 6 hours was not detected. The serum level reached the maximum at 1 hour after drip infusion and the level at 1 and 2 hours were 62 and 34 μg/ml, respectively, and the level at 6 hours was not detected.
PC-904 was clinically effective in 7 of 9 cases with bacterial infections in infants and children.
No side effects were observed except for the abnormality of the laboratory findings; elevation of BUN in 1 case, elevation of GOT in 2, and elevation of both GOT and GPT in 1.
